- Quell Therapeutics has partnered with eXmoor pharma to manufacture CAR-Treg therapies for autoimmune diseases.
- eXmoor will support Quell’s clinical manufacturing at its new Bristol facility.
Quell Therapeutics Ltd and eXmoor pharma have announced a strategic partnership to manufacture Quell’s autologous CAR-Treg cell therapies, aimed at treating autoimmune diseases. The agreement covers process transfer, scale-out, and Phase 1/2 clinical manufacturing for multiple candidates in Quell’s pipeline.
The collaboration will leverage Quell’s expertise in T-regulatory (Treg) cell therapies, including its Foxp3 Phenotype Lock™ technology and multi-modular platform. These technologies ensure that Quell’s CAR-Treg therapies are targeted, stable, and effective in modulating immune responses. Quell’s experience in manufacturing CAR-Treg candidates will be central to advancing its ongoing LIBERATE trial with QEL-001, targeting liver transplant patients.
eXmoor pharma, a newly licensed contract development and manufacturing organisation (CDMO), will provide manufacturing capacity at its state-of-the-art facility in Bristol, UK. eXmoor’s facility offers four GMP clean rooms, integrated process development labs, and capabilities for scaling up therapies. The company received its GMP license from the MHRA in August 2024, allowing it to support clinical manufacturing needs.
Aaron Vernon, Chief Manufacturing Officer at Quell, commented, “This partnership will provide increased capacity to manufacture our emerging pipeline of CAR-Treg product candidates and move them into clinical development.”
“Quell’s CAR-Treg expertise and our long-standing collaboration make them an excellent first manufacturing client in our new, state-of-the-art facilities and we are committed to creating a true partnership,” said Angela Osborne, CEO of eXmoor pharma.
Overview of outsourcing trends 
